Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Stryker Corporation is a medical devices business based in the US. Stryker Corporation shares (SYK) are listed on the NYSE and all prices are listed in US Dollars. Stryker Corporation employs 43,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $254.68 |
|---|---|
| 52-week range | $218.71 - $280.43 |
| 50-day moving average | $261.48 |
| 200-day moving average | $262.32 |
| Wall St. target price | $288.78 |
| PE ratio | 53.6856 |
| Dividend yield | $2.52 (1.04%) |
| Earnings per share (TTM) | $4.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $254.68 from 2022-01-21
| 1 week (2022-01-14) | -4.51% |
|---|---|
| 1 month (2021-12-22) | -3.55% |
| 3 months (2021-10-18) | N/A |
| 6 months (2021-07-22) | -1.71% |
| 1 year (2021-01-22) | 6.15% |
|---|---|
| 2 years (2020-01-22) | 17.33% |
| 3 years (2019-01-22) | 53.53% |
| 5 years (2017-01-20) | 109.18% |
Valuing Stryker Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stryker Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stryker Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Stryker Corporation shares trade at around 54x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Stryker Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2122. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stryker Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Stryker Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.
The EBITDA is a measure of a Stryker Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.7 billion |
|---|---|
| Operating margin TTM | 21.95% |
| Gross profit TTM | $9.2 billion |
| Return on assets TTM | 6.89% |
| Return on equity TTM | 13.99% |
| Profit margin | 11.4% |
| Book value | $37.58 |
| Market capitalisation | $100.6 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Stryker Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 33.93
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Stryker Corporation's overall score of 33.93 (as at 12/31/2018) is pretty weak – landing it in it in the 71st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Stryker Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.06/100
Stryker Corporation's environmental score of 3.06 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Stryker Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.68/100
Stryker Corporation's social score of 14.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Stryker Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.19/100
Stryker Corporation's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Stryker Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Stryker Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Stryker Corporation hasn't always managed to keep its nose clean.
Stryker Corporation was last rated for ESG on: 2019-01-01.
| Total ESG score | 33.93 |
|---|---|
| Total ESG percentile | 70.66 |
| Environmental score | 3.06 |
| Environmental score percentile | 1 |
| Social score | 14.68 |
| Social score percentile | 1 |
| Governance score | 8.19 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Dividend payout ratio: 28.13% of net profits
Recently Stryker Corporation has paid out, on average, around 28.13% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.04% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Stryker Corporation shareholders could enjoy a 1.04% return on their shares, in the form of dividend payments. In Stryker Corporation's case, that would currently equate to about $2.52 per share.
While Stryker Corporation's payout ratio might seem fairly standard, it's worth remembering that Stryker Corporation may be investing much of the rest of its net profits in future growth.
Stryker Corporation's most recent dividend payout was on 30 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 29 December 2021 (the "ex-dividend date").
Stryker Corporation's shares were split on a 2:1 basis on 16 May 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Stryker Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Stryker Corporation shares which in turn could have impacted Stryker Corporation's share price.
Over the last 12 months, Stryker Corporation's shares have ranged in value from as little as $218.7128 up to $280.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Stryker Corporation's is 1.0106. This would suggest that Stryker Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.